Searched for
PHARMA TARIFFS NEWS
'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...- For investors with long-term perspective: 5 mid-cap stocks from different sectors with upside potential of up to 30%Even before the US-Israel-Iran war began, there was a sort of readjustment taking place in the mid-cap segment – a kind of valuation readju...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%If you are putting fresh money into the market, it might be a good idea to stay with companies that don't have much to do with global suppl...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Pharma calls in sick after Trump’s 100% tariff threatPharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Tariff pause eases pressure on drug companiesIndian drug makers can breathe easier as the US reportedly shelves plans for tariffs on generic drug imports. This move is a significant re...
- Trump delivers another bitter tariff pill. Who’s set to bite the dust?A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unles...
- More tariffs by Trump: Branded pharma hit with 100% duty, and the list doesn't end thereDonald Trump plans new import taxes from October 1. Taxes include 100% on medicines, 50% on kitchen items, 30% on furniture, and 25% on hea...
- Pharma tariffs may go as high as 250%, says TrumpU.S. President Donald Trump said new tariffs on imported pharmaceuticals will start small but could rise to 250% within 18 months to boost ...
- Aditya Khemka on US tariff threat over pharma and what to bet on thereInCred Asset Management is cautious about US-facing generic pharma companies due to potential tariff risks and single-digit earnings growth...
- Markets in pause mode as tariff uncertainty lingers: Sudip BandyopadhyayThe market is currently in a wait-and-watch mode. News related to specific sectors is driving market reactions. Copper and pharma sectors a...
- IT stocks to recover if there's no slowdown in the US: Krishnan VRI think on fundamentals alone the broader financial services sector presents attractive opportunities in insurance, wealth management etc. ...
- Pharma stocks in focus as Trump signals tariffs on imported medicinesPresident Trump announced potential tariffs on imported pharmaceuticals, impacting countries like India, a major supplier to the US drug ma...
- Trump tariff hike hits Dalal Street: 4 sectors facing the biggest impact, global brokerages decodeThe Trump administration's 26% tariff on Indian imports has led to significant market reactions and economic concerns. Pharmaceuticals rema...
- No chill, just pills! Pharma stocks slide up to 8% as Trump does yes-no-yes on tariffShares of Indian pharma companies, including Aurobindo Pharma, Laurus Labs, IPCA Labs, and Lupin, fell up to 8% after U.S. President Donald...
- Ahead of Trump's tariff announcement, pharma bodies brace for big shake-up: What could happen next?Drugmakers are lobbying President Trump to phase in tariffs on imported pharmaceutical products to alleviate the impact and allow time for ...
- Top Indian drugmakers bank on bilateral talks for relief from planned US tariffsIndian pharmaceutical companies are expected to maintain their strong presence in the U.S. generic drug market despite possible high tariff...
- Global trends point to recovery, India to follow suit: Sandip SabharwalSo, I do not think it is going to last unless and until the call is that the entire emerging market move will again reverse and all the eme...
Load More
